Royalty Report: Drugs, DNA, Drug Discovery – Collection: 344487

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • DNA
  • Drug Discovery
  • Genome
  • Disease
  • Cancer
  • Molecular
  • Diagnostic
  • Delivery
  • Therapeutic
  • ribonucleic acid
  • Respiratory
  • Proteins
  • Test/Monitoring

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 344487

License Grant
The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants to Licensee, grants the French Licensee an exclusive license for the patents to make, have made, use and sell the Licensed Products and/or implement or have implemented the Licensed Process in the Territory in the Field.

The Licensor has already granted exploitation rights under the Patents to Third Parties for the production of the enzyme I-SceI, the use of the plasmid pSCM525, and, internal research.  Consequently, the term exclusive is understood for the purposes of the present agreement as the Licensor being prohibited from exploiting or having exploited or granting a license or exploitation rights under the Patents to a Third Party in the Field, other than those already granted.

License Property
The University is the owner of patents and patent applications relating to the gene of enzyme I-SceI, the expression of the enzyme I-SceI and its use.

The patent is titled Nucleotide sequence encoding the enzyme I-SceI and the uses thereof.

Field of Use
The Field is understood as any application of the Licensed Products and Licensed Process, in particular with to homologous recombination, excluding the applications for which rights have already been granted.  Homologous recombination is a type of genetic recombination in which genetic information is exchanged between two similar or identical molecules of double-stranded or single-stranded nucleic acids (usually DNA as in cellular organisms but may be also RNA in viruses). It is widely used by cells to accurately repair harmful breaks that occur on both strands of DNA, known as double-strand breaks (DSB).

IPSCIO Record ID: 372419

License Grant
This amendment 4 expands the field.  The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases and vaccines, and Licensee now agree to further modify the scope of the Agreement to include new patent families and expand the field to include all therapeutic applications in the Field.
License Property
The license is on a patented specific nucleotide sequence having a triplex structure, referred to as DNA flap.

Gene therapy shall mean the use of a vector containing at least one DNA sequence that encodes at least one protein or other molecule, in order to restore the functional activity of one or more resident non-functional gene copies, or provide for the introduction and expression of novel protein(s) or molecule(s) not normally expressed in the cell type or expression of protein(s) or molecule(s) that do not exist normally in nature.  The introduced protein(s) or molecule(s) are not intended to generate a prophylactic and/or therapeutic immune response against the protein or molecule encoded by the introduced DNA sequence of interest for use in Vaccination.

Field of Use
The Field shall mean Gene therapy for the treatment and prevention of human disorders, including, without limitation, the use of chimeric antigen receptor T-cells.

Chimeric antigen receptor cells is a special receptor created in the laboratory that is designed to bind to certain proteins on cancer cells. The chimeric antigen receptor is then added to immune cells called T cells.

IPSCIO Record ID: 336350

License Grant
The French Institute grants to the French Licensee an exclusive license under the Agreement Patents to make, have made, use and sell the Licensed Products and/or implement or have implemented the Licensed Process in the Territory in the Field.

The amendment 2 updates the field of use.

License Property
Licensor is owner of patents and patent applications relating to a method of homologous recombination.

The patent is titled “procédé de remplacement spécifique d’une copie d’un gène present dans le genome receveur par l’intégration d’un gène different de celui où se fait l’intégration”

Field of Use
The Field of this Agreement concerns the field of homologous recombination applied to any genes excluding cytokines, hormones and human growth factors.

The Amendment 2 clarifies  
This exclusion does not apply in either of the following cases
–  As part of the creation of test animals used as a research and medication screening and validation tool;
–  As part of use combined with the PGN patents on the one hand and I-SceI and/or I-Spom I and/or Mulligan on the other hand, excluding applications for Erythropoietin (EPO).

Amendment 3 clarifies
The Field covers the field of homologous recombination applied to all genes other than those that code for Erythropoietin (EPO).

IPSCIO Record ID: 336355

License Grant
The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants to Licensee, grants to the French Licensee an exclusive license, to the Licensor patents  to make, have made, use and sell the Licensed products and/or implement the licensed process in the territory is the field.

This license is non-exclusive for the Licensed process applied to human gene therapy.

The Licensor grants an immediate, complete and free access to the Know-how.

License Property
The patents and know-how relate to processes of homologous recombination using meganucleases.
Field of Use
The Field is understood as any application of the Licensed Products and Licensed Process.

Licensor has agreed to share with a joint Licensor exploitation rights of the inventions of these patent applications and now wishes to share its rights under this technology with a industrial partner.

Licensee has as its activity the domain of genome and anti-viral therapy, the production of genomically-modified organisms, with respect to offering services to third parties, the sale of molecular biology products and reagents, the development of new therapeutic strategies, alone or in cooperation with pharmaceutical laboratories.

IPSCIO Record ID: 372469

License Grant
The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants a license under the Patents in the Field and in the Territory for research and development, and to manufacture, have manufactured, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import or have imported the Products, to the exclusion of any other rights, which is
—  exclusive for Products containing human (HIV-1 and HIV-2) lentivirus vector, and;
—  non exclusive for Products containing non-human lentivirus vector.
License Property
Licensor has identified and patented a specific nucleotide sequence having a triplex structure, referred to as DNA flap, covered by patents and patent applications.

Ex vivo gene therapy shall mean that cells are extracted from a patient, corrected by placing a healthy or functional gene and transplanted back into patient.

Field of Use
Field shall mean ex vivo gene therapy for human disorders limited to adrenoleukodystophy (ALO) (including but not limited to AMN, CCALD, and all other variants of this disease caused by genetic mutations), beta hemoglobinopathies (including but not limited to betathalassemia and sickle cell anemia), (hemophilia, lysosomal storage disorders (LSDs, including Gaucher disease, Fabry disease, Pompe disease or GAA deficiency, and mucopolysaccharidosis I, II and VI), HIV/AIDS, eye diseases (including but not limited to AMD and Stargardt disease), and Parkinsons Disease; for Parkinsons Disease and eye diseases (including but not limited to AMD and Stargardt disease)].  The Field includes in vivo as well as ex vivo gene therapy.

IPSCIO Record ID: 209527

License Grant
The Swiss Licensor grants a nonexclusive license in the territory, without the right to sublicense except to its current affiliates as follows
– under TAQ patent rights, to manufacture, but not to have manufactured, to use and to sell, strictly under Licensees or its Affiliates own Trademarks, Tradenames and/or label(s), TAQ Reagents; and
– under Polymerase patent rights, to manufacture, but not to have manufactured, to use and to sell, strictly under Licensees or its Affiliates own Trademarks, Tradenames and/or label(s), Licensor Patented Enzymes other than TAQ Reagents.
License Property
The Licensor Patented Enzymes licensed herein are
a)  native Taq DNA Polymerase, full length, unmutated
b)  recombinant Taq DNA Polymerase, full length, unmutated
c)  Tth DNA Polymerase, full length, unmutated (native or recombinant)

The Licensed Researched Products are any product, including but not limited to kits, which products consist of or contain a Licensed Product and may include all or some of the following components  buffers, nucleotides, enzymes, or other reagents or materials.

Licensed Application Products are Application Kits for a Licensed Application Field or reagents, components or other materials which are sold in connection with the sale of an Applications Kit for a Licensed Application Field by Invitrogen and which are adapted for or promoted or supported for use by customers in PCR Testing or nucleic acid sequencing, or RT AND RT-PCR in Application Fields.

Field of Use
The Application fields include Forensics and Human Identity Applications, Environmental Testing, Agricultural Plant, Animal Identity Testing and Positive Trait Breeding Applications and Food Testing.

IPSCIO Record ID: 372479

License Grant
The Parties now agree to further expand the Field to include human and non-human lentivirus.

And the grant is restated as
The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants a license under the Patents in the Field and in the Territory for research and development, and to manufacture, have manufactured, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import or have imported the Products, to the exclusion of any other rights, which is
– exclusive for Products containing or based on any lentivirus vector including human and non-human lentivirus.

In addition, Licensor grants a nonexclusive license under the Patents in the Field and in the Territory to make or to have made by a Thirty Party Good Manufacturing Practice (GMP) batches of lentiviral vectors for its/their own clinical trials on Products, provided that such Third Party makes Good Manufacturing Practice (GMP) batches of lentiviral vectors solely for the Licensee and its Affiliates and sublicensees clinical trials of Products above mentioned.

License Property
The license is on a patented specific nucleotide sequence having a triplex structure, referred to as DNA flap.

Lentivirus is a genus of retroviruses that cause chronic and deadly diseases characterized by long incubation periods, in humans and other mammalian species. The genus includes the human immunodeficiency virus, which causes AIDS.

Field of Use
The Field shall mean ex vivo Gene therapy for human disorders limited to adrenoleukodystophy (ALD) (including but not limited to AMN, CCALD, and all other variants of this disease caused by genetic mutations), beta hemoglobinopathies (including but not limited to beta-thalassemia and sickle cell anemia), (hemophilia, lysosomal storage disorders (LSDs, including Gaucher disease, Fabry disease, Pompe disease or GAA deficiency, and mucopolysaccharidosis I, II and VI), HIV/AIDS,) leukemias, lymphomas, B-cell malignancies and solid tumors by producing chimeric antigen receptor T-cells (that target specific tumor antigens (TSA), including those TSA that are specific to B cell malignancies and solid tumors and are present only on tumor cells and not on any other cell, and/or tumor-associated antigens which are present on some tumor cells and also some normal cells, autoimmune diseases, eye diseases (including but not limited to AMD and Stargardt disease), and Parkinsons Disease); for [Parkinsons Disease,) and [eye diseases (including but not limited to AMD and Stargardt disease)).  The Field includes in vivo as well as ex vivo Gene therapy.

IPSCIO Record ID: 210375

License Grant
Pursuant to this License agreement between the Licensee and a Swiss third party, is the right to use a license for intellectual property exclusively licensed to this Licensor by the third party.   A license under the Amplification Patent Rights for automated performance of the PCR Process in the Research Field based on the capacity of thermal cyclers used, and a running-royalty component for each use of the process.  In consideration of Licensees payment of the license issuance fee and of royalties on sales of Licensed Research Products, the Third Party grants to Licensee, in the Territory, limited, nonexclusive rights, without the right to sublicense except to its current Affiliates
a)     Licensee is hereby authorized to sell, strictly under Licensees or it Affiliates own Trademarks, Tradenames and/or label(s), Licensed Research Products with a label conveying to end-user purchasers the running-royalty component of a license under the Amplification Patent Rights to use such Licensed Research Products in or with the PCR Process strictly for such purchasers own internal use in the Research Field in conjunction with a thermal cycler whose use is covered by the up-front fee component, either by payment to Licensor or as purchased, and
b)     Licensee may promote Licensed Research Products for such use in or with the PCR Process in the Research Field.  The up-front component of the PCR license for research must be obtained by the end user in order to have a complete license for the automated performance of the PCR Process.  The up-front component may be purchased from Licensor.  Alternatively, it may be obtained through the purchase of thermal cycler(s) or temperature cycling instrument(s) bearing a valid label conveying to purchasers the up-front  component of the license, that is, an Authorized Thermal Cycler.
License Property
The Authorized Thermal Cycler means a thermal cycler or temperature cycling instrument whose use in automated performance of the PCR Process in the Research Field and Application Fields is covered by the up-front fee component of a PCR Process license.  The up-front component of that license may be purchased from Licensor.  Alternatively, the up-front component of that license may be obtained through the purchase of thermal cycler(s)  or temperature cycling instrument(s) bearing a valid label conveying the up-front PCR Process license component.

The Swiss third party Patented Enzymes licensed herein are
a)  native Taq DNA Polymerase, full length, unmutated
b)  recombinant Taq DNA Polymerase, full length, unmutated
c)  Tth DNA Polymerase, full length, unmutated (native or recombinant)

The Licensed Researched Products are any product, including but not limited to kits, which products consist of or contain a Licensed Product and may include all or some of the following components  buffers, nucleotides, enzymes, or other reagents or materials.

Licensed Application Products are Application Kits for a Licensed Application Field or reagents, components or other materials which are sold in connection with the sale of an Applications Kit for a Licensed Application Field by Invitrogen and which are adapted for or promoted or supported for use by customers in PCR Testing or nucleic acid sequencing, or RT AND RT-PCR in Application Fields.

Field of Use
The Application fields include Forensics and Human Identity Applications, Environmental Testing, Agricultural Plant, Animal Identity Testing and Positive Trait Breeding Applications and Food Testing.

IPSCIO Record ID: 344567

License Grant
Licensor grants
For the Development License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Profit-Share Territory, and an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Royalty Territory.

For the Commercialization License, an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology to Commercialize Licensed Products in the Field in the Territory.

For the Manufacturing License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Manufacture or have Manufactured Licensed Products for Development and Commercialization in the Field for the Territory.

License Property
Patents includes, among other
RNAI Modulation of RSV and Therapeutic Uses Thereof,
Inhaled Treatment for RSV,
Methods and Compositions for Prevention or Treatment of RSV Infection,
Model for RSV Infection,
Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences,
Use of Double Stranded RNA For Identifying Nucleic Acid Sequences That Modulate the Function of a Cell, and, Influenza siRNA Molecules, Expression Constructs. Compositions. and Methods of Use.

Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.

ALN-RSV01 is a synthetic double-stranded RNA (dsRNA) oligonucleotide formed by the hybridization of two partially complementary single-strand RN As in which the 3 ends of each strand are capped with two thymidine units (dT).

ALN-RSVO1 drug product is formulated as a sterile phosphate-buffered solution for dilution with normal saline prior to administration.

Licensed Products means any RNAi Product directed to RSV.

RSV means all strains of the respiratory syncytial virus.

RSVOl Product means any product containing Licensors proprietary composition known as ALN-RSVO1.

RSV02 Product means any product containing Licensors proprietary composition designated by the JSC as ALN-RSV02.

Field of Use
ALN-RSV01 is currently in Phase II clinical development for the treatment of respiratory syncytial virus (RSV) infection in adult lung transplant patients, as well as several other potent and specific second-generation RNAi-based RSV inhibitors in pre-clinical studies.

Directly Competitive Product means any therapeutic or prophylactic product that specifically targets RSV. For avoidance of doubt, Directly Competitive Product as to a Party shall not include a product with broad antiviral activity that may also target RSV as long as any Development of such product as a treatment or
prophylaxis of RSV in humans has been limited to discovery, research and preclinical Development work up to, but not including, IND-enabling studies.

Licensee will develop and commercialize such therapeutic RNA interference products for the treatment of respiratory infections in humans caused by RSV, throughout the world, excluding Japan and certain other countries in Asia.

IPSCIO Record ID: 128301

License Grant
For the Licensee products, Licensor grants a non-exclusive, non-transferable, worldwide license, without the right to grant sublicenses, under Licensor Technology and Licensor Patents to perform research and preclinical development in the Field during the research term using Licensee research genes.

Licensor grants a non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee research genes exercisable during the research term of this Agreement.

Licensor grants an exclusive worldwide license, with the right to grant sublicenses, under Licensor Technology and Patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.

License Property
The Licensors patents include the Delivery of Exogenous DNA Sequences in a Mammal and the Production of Pharmaceutical-Grade Plasmid DNA.
Field of Use
The field is the intervention, treatment and/or prevention of a disease or disorder in humans by Gene therapy.

IPSCIO Record ID: 203979

License Grant
Licensor grants a nonexclusive, non-transferable, worldwide license, without the right to grant sublicenses, under Licensors technology and patents to perform research and preclinical development in the field during the research term using Licensee research genes.

Licensor grants non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee identified Research Genes exercisable during the research term of this Agreement.

With respect to exclusive Licensee products directed to a Licensee research gene for which Licensee has exercised an option Licensor is obligated to grant a license.  Licensor grants to Licensee an exclusive worldwide license under Licensor technology and patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.

License Property
The Licensed patents include the Delivery of Exogenous DNA Sequences in a Mammal and the Production of Pharmaceutical-Grade Plasmid DNA.
Field of Use
The field is the intervention, treatment and/or prevention of a disease or disorder in humans by Gene therapy.

IPSCIO Record ID: 203497

License Grant
Licensor grants to the Licensee of Denmark a worldwide, exclusive, irrevocable and sublicensable right and license to practice the Licensor Patents, the Licensor Know-How, the Licensor Future Patents, the Jointly Owned Patents and the Licensor Break-through Inventions to make, have made, use, promote, market distribute and sell Licensed Products within the Licensees Field and any Licensee Preferred Areas which may be activated.
License Property
Licensor has developed and possesses expertise, know-how and intellectual property rights within the generic field of in vitro and in vivo Shuffling.  The term In Vitro Shuffling shall mean Shuffling where the gene recombination event occurs outside of a cell, but shall not include any Assay Technology.

The Licensor Break-through Invention shall be an invention that is the result of extraordinary research and development activities and shall result from or be based on materially new and/or different application(s) of Shuffling, as compared to technology already in-licensed by Licensee hereunder or from third party or otherwise available to Licensee, that was neither invented nor foreseen by Licensor as of the Effective Date, thereby enabling Licensee to develop either new market(s) or materially improved profitability in existing markets for Industrial Proteins, including but not limited to materially reducing the cost of a manufacturing process, as compared to average existing industrial enzymes markets.

The term Shuffling shall mean new methods for recombination of genetic material for creation and screening of genetic diversity.   The term In Vitro Shuffling shall mean Shuffling where the gene recombination event occurs outside of a cell, but shall not include any Assay Technology.   The term In Vivo Shuffling shall mean Shuffling where the gene recombination event occurs inside of a cell, but shall not include any Assay Technology.

Field of Use
The Licensees Field shall cover development, production and sales of Industrial Proteins for use in
• textiles and leather,
• laundry and cleaning products,
• starch processing, which shall include carbohydrate synthesis and modification as they may be applicable to starch processing,
• baking,
• food (including, without limitation, fats and oil, protein hydrolysates, bulk flavor ingredients, thickeners, emulsifiers, texturizers, alcohol, brewing products, vegetable and fruit processing, wine, juice, OTC digestive aids that have never been non-OTC pharmaceutical products,
• feed,
• personal care products, skin care (including bath and shower) and hygiene products, but not including any therapeutic or pharmaceutical products,
• paper and pulp manufacture,
• oil drilling,
• dyestuffs and dyeing processes, insofar as no pathways other than Industrial Protein Expression Pathways are Shuffled,
• wood, pulp, paper, lignin, and cellulose processing,
• The Licensee Preferred Area(s) upon activation by Licensee as well as  the use of Shuffling for the development of organisms and vectors for the expression of the foregoing Industrial Proteins, including, but not limited to, the use of Shuffling to improve Industrial Protein Expression Pathways and competency of recombinant hosts, provided that the use of such organisms and vectors by Licensee or its Affiliates or licensees shall be limited to such purpose.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.